North Carolina Biotechnology Center

www.ncbiotech.org

The North Carolina Biotechnology Center accelerates life science technology-based economic development through innovation, commercialization, education, and business growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences | June 01, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More

Medical

PANCREATIC CANCER CELLS HARNESS NORMAL TISSUE TURNOVER TO BUILD PROTECTIVE BARRIERS

NYU Langone Health | April 05, 2022

news image

In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds. Led by researchers from NYU Grossman School of Medicine, the study revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue. Collagen protein fibers, the major component of the mesh, are continually broken down and replaced to maintain tensi...

Read More

Industrial Impact

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

news image

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More

Cell and Gene Therapy

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

news image

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More
news image

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences | June 01, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More
news image

Medical

PANCREATIC CANCER CELLS HARNESS NORMAL TISSUE TURNOVER TO BUILD PROTECTIVE BARRIERS

NYU Langone Health | April 05, 2022

In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds. Led by researchers from NYU Grossman School of Medicine, the study revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue. Collagen protein fibers, the major component of the mesh, are continually broken down and replaced to maintain tensi...

Read More
news image

Industrial Impact

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More
news image

Cell and Gene Therapy

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More